[Fundamental and clinical studies on ceftazidime]

Area of Science:

• Pharmacology and Therapeutics
• Obstetrics and Gynecology
• Infectious Diseases

Context:

• Obstetrical and gynecological infections pose significant clinical challenges.
• Understanding drug distribution and efficacy is crucial for treatment optimization.
• Ceftazidime is a third-generation cephalosporin antibiotic with broad-spectrum activity.

Purpose:

• To evaluate the pharmacokinetics and clinical efficacy of Ceftazidime (CAZ) in patients with obstetrical and gynecological infections.
• To assess CAZ drug transfer into uterine tissues and pelvic exudates.
• To determine the clinical effectiveness and safety profile of CAZ in this patient population.

Summary:

• Ceftazidime (CAZ) showed satisfactory transfer into uterine and adnexal tissues, maintaining high concentrations in pelvic dead space exudate.
• In 12 patients with obstetrical and gynecological infections, CAZ (approx. 4 g/day for 4-11 days) yielded satisfactory clinical effects in 9 patients.
• One patient experienced mild GOT elevation; no other significant side effects or abnormal laboratory values were noted.

Impact:

• Provides evidence for the utility of Ceftazidime in managing complex pelvic infections.
• Highlights the favorable pharmacokinetic profile of CAZ in gynecological and obstetrical settings.
• Supports the use of Ceftazidime as a safe and effective therapeutic option for these infections.